ethyl (2E,4E)-5-(4-methoxyphenyl)-3-methyl-2,4-pentadienoate | 64003-80-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: ethyl (2E,4E)-5-(4-methoxyphenyl)-3-methyl-2,4-pentadienoate
• 英文别名: ethyl 5-(4-methoxyphenyl)-3-methyl-2,4-pentadienoate；ethyl (2E,4E)-5-(4-methoxyphenyl)-3-methylpenta-2,4-dienoate
• CAS: 64003-80-1
• 化学式: C₁₅H₁₈O₃
• 分子量: 246.306
• InChiKey: VMUKVOQCFHDCTR-HDZHTHRUSA-N

物化性质

• 熔点：
  34 °C
• 沸点：
  386.2±25.0 °C(Predicted)
• 密度：
  1.053±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl (2E,4E)-5-(4-methoxyphenyl)-3-methyl-2,4-pentadienoate 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 作用下， 生成 (2E,4E)-5-(4'-methoxyphenyl)-3-methyl-2,4-pentadienal
  参考文献：
  名称：

  Photocurrents of solar cells sensitized by aggregate-forming polyenes: Enhancement due to suppression of singlet–triplet annihilation by lowering of dye concentration or light intensity

  摘要：

  Titania-based Gratzel-type solar cells were fabricated by the use of polyene dyes with various transition dipole moments. in the dye having the largest transition dipole among the samples, an aggregate was readily formed through dispersive interaction, and the photocurrent was increased when the dye concentration or the light intensity was lowered. This observation was ascribed to the suppression of the singlet-triplet annihilation reaction. In the dye having the smallest transition dipole, there was no sign of aggregate formation, and the photocurrent was decreased when the dye concentration or the light intensity was lowered. (c) 2006 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.cplett.2006.01.003
• 作为产物：
  描述：

  3-甲基-2-丁烯酸乙酯 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 生成 ethyl (2E,4E)-5-(4-methoxyphenyl)-3-methyl-2,4-pentadienoate
  参考文献：
  名称：

  脱落酸芳香类似物的合成及生物学效应

  摘要：

  摘要 使用 Reformatsky 和 ​​Wittig 反应合成了 36 种不同的 3-甲基-5-芳基-2,4-戊二烯酸和酯。不同的几何异构体可以通过干柱技术方便地分离。戊二烯侧链的构型分配基于NMR和UV特性。ABA 芳香族类似物的生物活性在四种生物测定中确定。大多数类似物的活性低于天然激素。在所有四种生物测定中，只有 3-methyl-5-p-chlorophenyl Δ 2 - trans , Δ 4 - trans -pentadienoic acid 表现出高 ABA 样活性。

  DOI：

  10.1016/s0031-9422(00)94349-8

文献信息

• Compounds and pharmaceutical preparations having calcium - regulatory activity
  申请人：University of Lancaster

  公开号：EP0240257A2

  公开（公告）日：1987-10-07

  Pharmaceutical compositions useful in regulating calcium transport across cellular membranes in man and ani­mals are disclosed. The compositions contain plant growth regulators such as abscisic acid and its derivatives. In particular, the compositions contain a compound of the for­mula: or R₁ - Y - R₂ wherein R₁ is an alkyl of up to seven carbons or a saturated or unsaturated six membered carbon ring, which may be sub­stituted; R₂ is a cyano group, a thio or hydroxy lower alkyl group or a group containing a carbonyl, most commonly a carboxyl group; R₃ is hydrogen or lower alkyl; R₄ is hydro­gen, lower alkyl or halide; R₅ is hydrogen or hydroxy; R₆ is hydrogen, carboxy or carboxy lower alkyl, or R₅ and R₆ form a bond between the carbons to which they are attached or with the carbons to which they are attached form a carbon ring; or R₂ and R₆ together with the carbon to which they are bonded form a heterocyclic ring; n is 0 or 1, with the proviso that when n is 0, R₂ is an acyl group; X is -CH₂-, -­CH=CH-, -CH₂-CH₂-, -CH₂-NH-, -CH₂-O-, -CH₂-S- or -NH-CO-; and Y is a carbocyclic group bonded to R₁ and R₂ through a single carbon. The compositions are formulated for oral, parenteral or other form of administration in dosages neces­sary to effect the desired change in calcium flux. Daily doses of 0.01 to 200 mg/kg in one or more doses are contem­plated. Dosage units may be formulated with any pharma­ceutically acceptable carrier which is compatible with the active ingredient.

  本发明公开了可用于调节人和动物细胞膜钙转运的药物组合物。这些组合物含有植物生长调节剂，如脱落酸及其衍生物。特别是，组合物中含有一种式的化合物： 或 R₁ - Y - R₂ 其中，R₁ 是最多七个碳原子的烷基或饱和或不饱和的六分子碳环，可以被取代；R₂ 是氰基、硫代或羟基低级烷基或含有羰基的基团，最常见的是羧基；R₃ 是氢或低级烷基；R₄ 是氢、低级烷基或卤化物；R₅ 是氢或羟基；R₆ 是氢、羧基或羧基低级烷基，或 R₅ 和 R₆ 在所连接的碳之间形成键，或与所连接的碳一起形成碳环；或 R₂ 和 R₆ 与所连接的碳一起形成杂环；n 为 0 或 1，但当 n 为 0 时，R₂ 为酰基；X 为-CH₂-、-CH=CH-、-CH₂-CH₂-、-CH₂-NH-、-CH₂-O-、-CH₂-S-或-NH-CO-；Y 是通过一个碳与 R₁ 和 R₂ 键合的碳环基团。组合物配制成口服、肠外或其他形式的给药剂量，以实现所需的钙通量变化。日剂量为 0.01 至 200 毫克/千克，可考虑一次或多次给药。剂量单位可与任何与活性成分相容的药学上可接受的载体配制。
• Makin, S. M.; Mikerin, I. E.; Shavrygina, O. A., Journal of Organic Chemistry USSR (English Translation), 1984, vol. 20, # 11, p. 2109 - 2114
  作者：Makin, S. M.、Mikerin, I. E.、Shavrygina, O. A.、Ermakova, G. A.、Arshava, B. M.

  DOI：——

  日期：——
• MAKIN, S. M.;MIKERIN, I. E.;SHAVRYGINA, O. A.;ERMAKOVA, G. A.;ARSHAVA, B.+, ZH. ORGAN. XIMII, 1984, 20, N 11, 2317-2323
  作者：MAKIN, S. M.、MIKERIN, I. E.、SHAVRYGINA, O. A.、ERMAKOVA, G. A.、ARSHAVA, B.+

  DOI：——

  日期：——